Intuitive Surgical Expands Manufacturing Footprint in Asia Pacific

Intuitive Surgical ISRG recently announced it will expand its manufacturing presence in Asia Pacific with a new facility in Penang, Malaysia, as the company looks to strengthen its ability to meet the rising demand for robotic-assisted surgery in the region. ISRG has entered into a lease agreement with Penang Development Corporation for a 316,000-square-foot manufacturing facility at Bandar Cassia Technology Park.

Per management, Asia Pacific represents a significant growth opportunity for Intuitive Surgical, given the rising adoption of robotic-assisted surgery across the region. The investment highlights the company’s long-term commitment to the region and should strengthen its ability to provide customers with innovative, high-quality and reliable products while potentially expanding access to robotic-assisted surgery.

Likely Trend of ISRG Stock Following the News

Following the announcement, shares of ISRG gained 0.2% at yesterday’s close. Year to date, shares of the company have declined 31% compared with the industry’s 8.4% loss. However, the S&P 500 has risen 12% in the same timeframe.

The new Penang facility is a positive development for ISRG as it expands production capacity in a region with substantial long-term potential for robotic-assisted surgery. Increasing local manufacturing capabilities should position the company to better serve healthcare providers, support rising demand for da Vinci systems and instruments and strengthen its competitive position in Asia Pacific.

ISRG currently has a market capitalization of $137.90 billion.

Image Source: Zacks Investment Research

More on the News

Asia Pacific remains an important growth market for Intuitive Surgical. Since entering Asia Pacific more than two decades ago, the company’s da Vinci surgical systems have enabled surgeons to treat more than 2.5 million patients across 13 markets.

The facility is expected to begin operations in 2028 and create approximately 1,200 highly skilled jobs by 2032. It will manufacture surgical instruments and electromechanical devices used with the da Vinci surgical system, expanding ISRG’s global manufacturing footprint and supporting the company’s growth across Asia Pacific.

Mark Brosius, executive vice president and chief Manufacturing and Supply Chain officer at ISRG, emphasized that the expansion is part of the company’s long-term strategy to strengthen its global manufacturing network while maintaining operational excellence. He added that the new facility will play an integral role in supporting the consistent delivery of high-quality and innovative products to customers and patients.

Penang chief minister Chow Kon Yeow said Intuitive’s investment underscores the company’s confidence in the region’s established industrial infrastructure, skilled workforce and manufacturing capabilities. The project will further strengthen Penang’s medical technology ecosystem and support its goal of becoming a leading MedTech hub in Southeast Asia.

ISRG has been witnessing continued growth in minimally invasive care globally, with its da Vinci system serving as a key driver. The company’s efforts to develop a broader robotic-assisted surgery ecosystem through technology, clinical education and collaboration with healthcare providers should further support adoption across Asia Pacific.

Industry Prospects Favoring the Market

Going by the data provided by Precedence Research, the Asia Pacific surgical robots market is predicted to be valued at $1.29 billion in 2026 and is expected to witness a CAGR of 11.6% through 2035.

The growth will be primarily driven by the growing preference for minimally invasive procedures. The rise in the aging population, incidence of chronic diseases and government-backed hospital modernization programs in multiple Asian countries are boosting demand for surgical procedures, thereby driving demand for robot-assisted surgeries.

Other News

Recently, ISRG ended the second quarter on a strong note, with earnings and revenues beating the Zacks Consensus Estimate. U.S. da Vinci procedure growth slowed to 12% in the second quarter from 14% in the first quarter, amid weaker elective procedures and uncertainty over ACA premium subsidies. Bariatric procedures declined at a high-single-digit rate due to growing GLP-1 adoption.

While Intuitive Surgical maintained its full-year procedure growth outlook, it did not raise guidance, citing tougher second-half comparisons. Concerns over the planned 2027 extension of instrument life could pressure recurring Instruments & Accessories revenues. However, strong da Vinci 5 adoption, rising SP and Ion procedures, broader ASC penetration, software and AI innovations, and international growth opportunities support the company’s long-term outlook.

Intuitive Surgical, Inc. Price

Intuitive Surgical, Inc. price | Intuitive Surgical, Inc. Quote

ISRG’s Zacks Rank & Key Picks

Intuitive Surgical currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO.

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research